Other Events ·
Niki BioSolutions, Inc. regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price…
NIKINiki BioSolutions, Inc.
Niki BioSolutions, Inc. regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. The company received a deficiency letter on March 5, 2026, after its stock closed below $1.00 for 30 consecutive business days. On August 4, 2026, Nasdaq confirmed that the closing bid price remained at or above $1.00 for ten consecutive business days from July 21 to August 3, 2026, resolving the compliance matter. Niki BioSolutions operates in the biotechnology industry, focusing on drug discovery and development.